buy on dips to be planned for investment

As of the latest available close on 11 September 2026, Apollo Hospitals was around ₹8,880–₹8,895. The stock is close to its 52-week high of roughly ₹9,050, so the long-term trend remains strong, but the stock is also trading at a premium valuation. 1. Business & Fundamental Analysis Apollo Hospitals is not just a hospital operator; its integrated healthcare ecosystem includes hospitals, pharmacy, diagnostics and digital healthcare. The FY26 numbers show strong improvement: Metric FY25 FY26 Change Revenue ₹21,794 Cr ₹25,228.5 Cr +15.8% Net Profit ₹1,472.1 Cr ₹1,957.8 Cr +33.0% EPS ₹100.56 ₹135.04 +34.3% ROE 17.60% 20.48% Improved Debt/Equity 0.64 0.60 Slightly improved The latest Q1 FY27 was also strong: revenue reached ₹7,043.5 crore (+20.6% YoY), EBITDA rose 27.4%, and net profit increased 34.2% to ₹580.7 crore. EBITDA margin improved to 16.4%. Fundamental verdict: 🟢 Strong The biggest positive is that profit is growing faster than revenue, indicating operating leverage and margin improvement. Another important development is Apollo's increased ownership of Apollo Health & Lifestyle, taking its stake to approximately 99.4%. So the long-term story is: More beds → higher occupancy → higher revenue → operating leverage → higher profitability 3. Technical Analysis At around ₹8,880, the technical setup is still constructive. Moving averages 20 EMA: ₹8,807 50 EMA: ₹8,741 100 EMA: ₹8,510 200 EMA: ₹8,142 Price is above all these important EMAs, which confirms a long-term bullish structure. Momentum RSI: 54.83 → neutral/healthy Stochastic RSI: bullish CCI: bullish MFI: bullish So there is no major RSI overbought warning at present, despite the stock being near its high. Important levels Immediate resistance: ₹8,990–₹9,050 Breakout: Sustained close above ₹9,050 Above ₹9,050, the stock can enter price-discovery territory. On the downside: Support 1: ₹8,800–₹8,740 Support 2: ₹8,500–₹8,510 Major support: ₹8,140–₹8,150